INSYS Therapeutics, Inc. - Product Pipeline Review - 2016
‘INSYS Therapeutics, Inc. - Product Pipeline Review - 2016’, provides an overview of the INSYS Therapeutics, Inc.’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by INSYS Therapeutics, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
‘INSYS Therapeutics, Inc. - Product Pipeline Review - 2016’, provides an overview of the INSYS Therapeutics, Inc.’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by INSYS Therapeutics, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
TELEPHONE: +1 (503) 894-6022<br />
E-MAIL: sales@researchbeam.com
The report provides comprehensive information on the therapeutics under<br />
development by <strong>INSYS</strong> <strong>Therapeutics</strong>, <strong>Inc</strong>., complete with analysis by stage of<br />
development, drug target, mechanism of action (MoA), route of<br />
administration (RoA) and molecule type. The report also covers the<br />
descriptive pharmacological action of the therapeutics, its complete<br />
research and development history and the dormant and discontinued<br />
projects.<br />
report features investigational drugs from across globe covering over 20<br />
therapy areas and nearly 3,000 indications. The report is built using data and<br />
information sourced from proprietary databases, company/university<br />
websites, clinical trial registries, conferences, SEC filings, investor presentations<br />
and featured press releases from company/university sites and industryspecific<br />
third party sources. Drug profiles featured in the report undergoes<br />
periodic review following a stringent set of processes to ensure that all the<br />
profiles are updated with the latest set of information.<br />
Read More At: http://www.researchbeam.com/insys-therapeutics-inc-productpipeline-review-<strong>2016</strong>-market
Scope<br />
• The report provides a snapshot of the pipeline therapeutic landscape of<br />
<strong>INSYS</strong> <strong>Therapeutics</strong>, <strong>Inc</strong>.<br />
• The report provides overview of <strong>INSYS</strong> <strong>Therapeutics</strong>, <strong>Inc</strong>. including its business<br />
description, key facts, and locations and subsidiaries<br />
• The report features descriptive drug profiles for the pipeline products which<br />
includes, product description, descriptive MoA, R&D brief, licensing and<br />
collaboration details & other developmental activities<br />
Reasons to buy<br />
• Evaluate <strong>INSYS</strong> <strong>Therapeutics</strong>, <strong>Inc</strong>.’s strategic position with total access to<br />
detailed information on its product pipeline<br />
• Gain strategically significant competitor information, analysis, and insights to<br />
formulate effective R&D strategies<br />
• Identify potential new clients or partners in the target demographic<br />
• Devise corrective measures for pipeline projects by understanding <strong>INSYS</strong><br />
<strong>Therapeutics</strong>, <strong>Inc</strong>.’s pipeline depth and focus of pipeline therapeutics<br />
Read More At: http://www.researchbeam.com/insys-therapeutics-inc-product-pipelinereview-<strong>2016</strong>-market
List of Tables<br />
<strong>INSYS</strong> <strong>Therapeutics</strong>, <strong>Inc</strong>., Key Information 5<br />
<strong>INSYS</strong> <strong>Therapeutics</strong>, <strong>Inc</strong>., Key Facts 5<br />
<strong>INSYS</strong> <strong>Therapeutics</strong>, <strong>Inc</strong>. - <strong>Pipeline</strong> by Indication, <strong>2016</strong> 7<br />
<strong>INSYS</strong> <strong>Therapeutics</strong>, <strong>Inc</strong>. - <strong>Pipeline</strong> by Stage of Development, <strong>2016</strong> 9<br />
<strong>INSYS</strong> <strong>Therapeutics</strong>, <strong>Inc</strong>. - Monotherapy <strong>Product</strong>s in <strong>Pipeline</strong>, <strong>2016</strong> 10<br />
<strong>INSYS</strong> <strong>Therapeutics</strong>, <strong>Inc</strong>. - Combination Treatment Modalities in <strong>Pipeline</strong><br />
<strong>INSYS</strong> <strong>Therapeutics</strong>, <strong>Inc</strong>. - Pre-Registration, <strong>2016</strong> 12<br />
<strong>INSYS</strong> <strong>Therapeutics</strong>, <strong>Inc</strong>. - Phase III, <strong>2016</strong> 13<br />
<strong>INSYS</strong> <strong>Therapeutics</strong>, <strong>Inc</strong>. - Phase II, <strong>2016</strong> 14<br />
<strong>INSYS</strong> <strong>Therapeutics</strong>, <strong>Inc</strong>. - Phase I, <strong>2016</strong> 15<br />
<strong>INSYS</strong> <strong>Therapeutics</strong>, <strong>Inc</strong>. - <strong>Pipeline</strong> by Target, <strong>2016</strong> 30<br />
<strong>INSYS</strong> <strong>Therapeutics</strong>, <strong>Inc</strong>. - <strong>Pipeline</strong> by Route of Administration, <strong>2016</strong> 32<br />
<strong>INSYS</strong> <strong>Therapeutics</strong>, <strong>Inc</strong>. - <strong>Pipeline</strong> by Molecule Type, <strong>2016</strong> 33<br />
<strong>INSYS</strong> <strong>Therapeutics</strong>, <strong>Inc</strong>. - <strong>Pipeline</strong> <strong>Product</strong>s by Mechanism of Action, <strong>2016</strong> 34<br />
<strong>INSYS</strong> <strong>Therapeutics</strong>, <strong>Inc</strong>. - Recent <strong>Pipeline</strong> Updates, <strong>2016</strong> 35<br />
<strong>INSYS</strong> <strong>Therapeutics</strong>, <strong>Inc</strong>. - Dormant Developmental Projects,<strong>2016</strong> 38<br />
<strong>INSYS</strong> <strong>Therapeutics</strong>, <strong>Inc</strong>. - Discontinued <strong>Pipeline</strong> <strong>Product</strong>s, <strong>2016</strong> 39<br />
<strong>INSYS</strong> <strong>Therapeutics</strong>, <strong>Inc</strong>., Other Locations 43<br />
<strong>INSYS</strong> <strong>Therapeutics</strong>, <strong>Inc</strong>., Subsidiaries 43<br />
Enquire More At: http://www.researchbeam.com/insys-therapeutics-inc-productpipeline-review-<strong>2016</strong>-market/enquire-about-report
Visit us at<br />
http://www.researchbeam.com/insys-therapeutics-inc-productpipeline-review-<strong>2016</strong>-market<br />
Stay With Us:<br />
TELEPHONE: +1 (800) 910-6452<br />
DIRECT: +1 (503) 894-6022<br />
E-MAIL: sales@researchbeam.com<br />
5933 NE Win Sivers Drive,<br />
#205, Portland, OR 97220<br />
United States
Change language